Do I Qualify for Wegovy, Zepbound or Another GLP-1, and Who Decides?
There is no application and no official qualification body. Three separate gates decide access: the FDA label, a prescriber's judgment, and your insurance plan. The weight-loss labels cover adults with obesity, or overweight plus at least one weight-related condition — and print no BMI number.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
There is no form to fill out and no official body that decides whether you “qualify” for Wegovy, Zepbound or another GLP-1 weight-loss drug — the prescribing information for these drugs describes no application process and names no qualification body [1] [2] [4]. Instead, three separate gates stand between you and the medication. First, the FDA label — the prescribing information printed for each drug — defines the group of patients the drug is indicated for [1] [2] [4] [7] [8]. Second, these are prescription drugs whose labels are written for healthcare providers, and a prescription requires a provider’s decision for an individual patient [1] [2] [4]. Third, your insurance plan or employer decides whether to pay for it, and that decision is made separately from the label [3].
The short version of who the weight-management labels cover: adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, always alongside a reduced-calorie diet and increased physical activity [1] [2] [4] [7]. Notably, none of these labels prints a BMI number in the indications section — the words “obesity” and “overweight” appear without a cutoff [1] [2] [4] [7].
Who exactly do the weight-loss labels cover?
Each drug’s prescribing information spells out its indicated population. Here is what the current labels say, drug by drug.
Wegovy injection is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight who have at least one weight-related comorbid condition [1]. The injection also carries two additional indications: reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight, and treating noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis, stages F2 to F3, in adults — the latter under accelerated approval [1].
Wegovy tablets are indicated for adults only: weight reduction in adults with obesity or overweight plus at least one weight-related comorbid condition, and cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight. No pediatric or MASH indication is listed for the tablets [1].
Zepbound (tirzepatide) injection is indicated for weight reduction in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, and separately to treat moderate to severe obstructive sleep apnea in adults with obesity [2].
Foundayo (orforglipron) tablets, whose label shows “Initial U.S. Approval: 2026,” are indicated for weight reduction in adults with obesity or adults with overweight plus at least one weight-related comorbid condition [4].
Saxenda (liraglutide) daily injection is indicated for adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, and for adults with overweight plus at least one weight-related comorbid condition [7].
All four of these weight-management labels require use together with a reduced-calorie diet and increased physical activity [1] [2] [4] [7].
| Drug | Active ingredient | Form | Who the weight label covers |
|---|---|---|---|
| Wegovy injection | Semaglutide | Weekly injection | Adults and pediatric patients aged 12+ with obesity; adults with overweight + at least one weight-related comorbid condition [1] |
| Wegovy tablets | Semaglutide | Daily tablet | Adults only: obesity, or overweight + at least one weight-related comorbid condition [1] |
| Zepbound | Tirzepatide | Weekly injection | Adults with obesity, or overweight + at least one weight-related comorbid condition; also moderate to severe OSA in adults with obesity [2] |
| Foundayo | Orforglipron | Daily tablet | Adults with obesity, or overweight + at least one weight-related comorbid condition [4] |
| Saxenda | Liraglutide | Daily injection | Adults and pediatric patients aged 12+ with body weight greater than 60 kg and obesity; adults with overweight + at least one weight-related comorbid condition [7] |
Is there a BMI number printed on the Wegovy or Zepbound label?
No. The indications sections for Wegovy, Zepbound, Foundayo and Saxenda all use the words “obesity” and “overweight” without printing any BMI cutoff [1] [2] [4] [7]. This surprises many people, because BMI thresholds such as “BMI 30” or “BMI 27 plus a comorbidity” are widely repeated online. Those numbers do not appear in the indications sections of the labels in these sources.
That does not mean BMI is irrelevant. It means the label leaves the measurement of “obesity” and “overweight” to clinical practice, and the numbers clinicians use come from medical guidelines, not from the drug label itself.
What BMI numbers do clinicians actually use?
The American Diabetes Association’s Standards of Care in Diabetes–2026 stages weight this way: overweight is BMI 25–29.9 kg/m², obesity class 1 is BMI 30–34.9, obesity class 2 is BMI 35–39.9, and obesity class 3 is BMI 40 or above [5]. The ADA recommends screening for overweight and obesity using BMI annually (recommendation 8.2a) [5].
The National Heart, Lung, and Blood Institute offers a free online BMI calculator, in standard or metric units, that uses height and weight. Its adult categories are: underweight below 18.5, healthy 18.5–24.9, overweight 25.0–29.9, and obesity 30.0 or above [6]. NHLBI cautions that BMI does not account for muscle mass, bone density or body composition, and that a healthcare provider will consider whether a given BMI is too high or too low for the individual [6].
| Category | BMI (kg/m²) |
|---|---|
| Underweight | Below 18.5 [6] |
| Healthy | 18.5–24.9 [6] |
| Overweight | 25.0–29.9 [5] [6] |
| Obesity class 1 | 30–34.9 [5] |
| Obesity class 2 | 35–39.9 [5] |
| Obesity class 3 | 40 or above [5] |
These numbers are information you can bring to a clinician, not a self-assessment of eligibility. Whether you meet the label’s terms is a judgment the prescriber makes.
What counts as a “weight-related comorbid condition”?
Here is the honest limit of the answer: the labels do not publish a list of qualifying comorbid conditions [1] [2] [4] [7]. The phrase “at least one weight-related comorbid condition” appears without a definition attached.
Some context exists in the sources. The ADA notes that obesity substantially increases the risk of the development and progression of type 2 diabetes [5]. A Business Group on Health survey notes that GLP-1s show promise in helping manage cardiovascular disease, obstructive sleep apnea and substance use disorder [3]. But neither of these statements is a label definition of which conditions count.
In practice, which conditions a plan accepts is a plan decision. Employers commonly validate clinical eligibility through “objective biometric data” requirements, meaning the plan — not the label — ends up defining what documentation counts [3].
What’s the difference between Wegovy and Ozempic, or Zepbound and Mounjaro?
Wegovy and Ozempic are both semaglutide [1] [8], and Zepbound is tirzepatide [2]. The brand names Ozempic, Wegovy, Mounjaro and Zepbound are commonly cited as GLP-1s, a class originally developed to help regulate blood sugar in people with type 2 diabetes [3]. What Mounjaro’s own label says has not been verified here, because that label text was unavailable.
The Ozempic label is written for adults with type 2 diabetes: improving glycemic control as an adjunct to diet and exercise; reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [8]. The Ozempic label carries no weight-loss indication [8].
Each label also states its own dosing information. The Wegovy injection label lists a usual recommended maintenance dosage of 2.4 mg once weekly [1]. The Ozempic label describes increasing the dosage stepwise up to 2 mg once weekly if additional glycemic control is needed [8].
Are there pill versions, or only injections?
There are now oral options. Wegovy tablets are taken once daily on an empty stomach in the morning with up to 4 ounces of water, waiting at least 30 minutes before food, beverages or other oral medications. They come in strengths of 1.5, 4, 9 and 25 mg [1].
Foundayo is a tablet taken orally once daily, with or without food, in strengths of 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg [4].
Employers are watching this shift closely: 87% anticipate that the availability of an oral GLP-1 will raise overall demand for the drugs, and only 9% expect a price decrease [3].
Can a 12-year-old be prescribed a GLP-1 for weight?
Two weight-management labels include pediatric patients. Wegovy injection covers pediatric patients aged 12 years and older with obesity [1]. Saxenda’s indication covers adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity — and the Saxenda label states that safety and effectiveness in pediatric patients with type 2 diabetes have not been established [7].
The other weight-management labels are written for adults only: Zepbound [2], Foundayo [4], and Wegovy tablets [1].
Who is absolutely barred from taking these drugs?
Every label in this group — Wegovy, Zepbound, Foundayo, Saxenda and Ozempic — contraindicates use in patients with a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1] [2] [4] [7] [8]. Each label also lists hypersensitivity to the active drug or any of its excipients as a contraindication [1] [2] [4] [7] [8].
All five carry a boxed warning about the risk of thyroid C-cell tumors. The Wegovy, Zepbound and Saxenda warnings cite rodent tumors at clinically relevant exposures; the Ozempic warning states that semaglutide causes thyroid C-cell tumors in rodents. All state that human relevance has not been determined [1] [2] [7] [8]. The Foundayo warning is worded differently: it states that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, while the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [4].
Beyond the hard contraindications, several labels say the drug is “not recommended” in certain situations. Zepbound, Foundayo, Saxenda and Ozempic are not recommended in patients with severe gastroparesis [2] [4] [7] [8]. Wegovy, Zepbound, Foundayo and Saxenda all state that concomitant use with another GLP-1 receptor agonist, or with other products containing the same molecule, is not recommended [1] [2] [4] [7]. Foundayo adds three more: it is not recommended in severe hepatic impairment, its maximum dosage is 9 mg once daily when used with a strong CYP3A4 inhibitor, and simvastatin should not exceed 20 mg once daily when taken with it [4].
What about pregnancy and birth control?
The Zepbound and Foundayo labels state the drugs may cause fetal harm and should be discontinued when pregnancy is recognized [2] [4].
The Ozempic label goes further on planning: it says to discontinue in women at least 2 months before a planned pregnancy, because of semaglutide’s long washout period [8].
Both Zepbound and Foundayo address oral contraceptives. Zepbound advises females using oral contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation [2]. Foundayo gives the same advice with a 30-day window after initiation and after each dose escalation [4].
Why does insurance say no even when the label says yes?
Because coverage is a separate decision made by the plan and the employer, and employers are under cost pressure. A Business Group on Health survey completed in February–March 2026 by 105 employer members found that 67% of surveyed employers currently cover GLP-1s for weight management, while most cover GLP-1s for diabetes [3].
Employers use a range of controls on weight-management coverage: validating clinical eligibility via objective biometric data, requiring participation in a weight management program, limiting prescribing to specific providers, and excluding certain medications from the formulary [3].
Coverage is not guaranteed to continue. Of employers covering GLP-1s for weight management, 72% said they were likely to continue that coverage in 2027, while 10% said they likely would not. Companies that do not cover GLP-1s for weight management today are unlikely to add coverage in the future [3].
Nearly eight in 10 employers report that GLP-1s are increasing their company’s health care costs, and nearly eight in 10 involve executive leadership in coverage decisions. When employees do get coverage, most employers (83%) apply the same standard cost-share as for other medications [3].
One wrinkle worth knowing: Zepbound carries a separate indication to treat moderate to severe obstructive sleep apnea in adults with obesity [2]. How a plan treats that indication is a plan decision — the survey shows employers set their own coverage rules, including formulary exclusions [3].
These survey figures describe large employers as a group. They do not tell you what any individual plan covers — that has to be verified with the plan itself.
| Employer survey finding (105 employers, February–March 2026) | Result |
|---|---|
| Currently cover GLP-1s for weight management | 67% [3] |
| Of those, likely to continue coverage in 2027 | 72% [3] |
| Of those, likely not to continue in 2027 | 10% [3] |
| Apply same standard cost-share as other medications | 83% [3] |
| Anticipate oral GLP-1s raise overall demand | 87% [3] |
| Anticipate a price decrease | 9% [3] |
Is BMI even the right measure for this decision?
The ADA is candid about BMI’s limits. BMI is not a perfect measure of adipose tissue mass; it does not measure fat distribution or function, and it does not factor in weight-related health consequences [5]. It is especially prone to misclassification in very muscular people, such as athletes, and in people with low muscle mass [5].
The ADA recommends confirming excess adiposity with direct body-fat measurement or at least one anthropometric criterion — waist circumference, waist-to-hip ratio, or waist-to-height ratio — particularly at BMI 25–34.9 and in South Asian individuals [5]. At the same time, the ADA says BMI remains an acceptable measure where additional measures aren’t feasible, noting that in US adults aged 20–59, obesity prevalence by BMI is nearly identical to prevalence after adiposity confirmation [5].
For context on why weight matters at all: the ADA states that weight loss of 5–7% of baseline weight improves glycemia and cardiovascular risk factors, and sustained loss of more than 10% usually confers greater benefit [5].
What should I do before and during the appointment?
A few concrete steps are supported by the sources:
Calculate your BMI with NHLBI’s free standard or metric calculator, which uses height and weight [6]. Bring the number as information for the clinician, not as a self-diagnosis.
Ask your plan whether weight-management GLP-1 coverage exists at all, and what biometric documentation or program participation it requires — those requirements are common employer controls [3].
Bring your family history of thyroid cancer or MEN 2, since a personal or family history of MTC or MEN 2 is a contraindication on every label in this class [1] [2] [4] [7] [8]. Bring your full medication list as well, because these drugs delay gastric emptying and can affect the absorption of oral medications [1] [2] [4] [7] [8].
Tell providers about any planned surgery or procedure. The labels for Zepbound, Foundayo, Saxenda and Ozempic all note reported cases of pulmonary aspiration during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists, and instruct patients to inform healthcare providers of planned surgeries or procedures [2] [4] [7] [8].
The final word on whether you qualify belongs to a prescriber weighing the label, your history and the contraindications — and, if cost matters to you, to whatever your plan decides to cover.
Sources
- National Library of Medicine, DailyMed. WEGOVY (semaglutide) injection, solution, drug label.
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. Initial U.S. approval: 2022.
- Business Group on Health. GLP-1 costs loom large for employers, forcing challenging coverage decisions, survey finds.
- National Library of Medicine, DailyMed. FOUNDAYO (orforglipron) tablet, film coated, drug label.
- PMC. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes–2026.
- National Heart, Lung, and Blood Institute. Calculate your BMI.
- National Library of Medicine, DailyMed. SAXENDA (liraglutide) injection, solution, drug label.
- National Library of Medicine, DailyMed. OZEMPIC (semaglutide) injection, solution, drug label.
- National Library of Medicine, DailyMed. RYBELSUS (oral semaglutide) tablet, drug label.
- National Library of Medicine, DailyMed. MOUNJARO (tirzepatide) injection, solution, drug label.
- National Library of Medicine, DailyMed. TRULICITY (dulaglutide) injection, solution, drug label.
- US Food and Drug Administration. Understanding unapproved use of approved drugs “off label.”
- PMC. Definition and diagnostic criteria of clinical obesity.
- Medicare.gov. Weight loss drugs.
- US Food and Drug Administration. FDA approves first new molecular entity under national priority voucher program.
Frequently asked questions
Is there a BMI number written on the Wegovy or Zepbound label?
No. The indications sections for Wegovy, Zepbound, Foundayo and Saxenda use the words "obesity" and "overweight" without printing any BMI cutoff. BMI numbers like 25–29.9 for overweight and 30 or above for obesity come from clinical guidance, such as the ADA Standards of Care and NHLBI, not from the drug labels.
Can Ozempic be prescribed for weight loss alone?
The Ozempic label carries no weight-loss indication. It is indicated for adults with type 2 diabetes — glycemic control, cardiovascular risk reduction with established cardiovascular disease, and kidney-related risk reduction with chronic kidney disease. Wegovy, which is also semaglutide, is the brand with the weight-management label.
What's the difference between Wegovy and Ozempic, or Zepbound and Mounjaro?
Wegovy and Ozempic are both semaglutide, and Zepbound is tirzepatide. The Ozempic label is written for adults with type 2 diabetes, while the Wegovy label carries the weight-management indication. Ozempic, Wegovy, Mounjaro and Zepbound are commonly cited GLP-1 brand names originally developed for blood sugar control in type 2 diabetes.
Can a 12-year-old be prescribed a GLP-1 for weight?
Two labels cover adolescents. Wegovy injection covers pediatric patients aged 12 years and older with obesity. Saxenda covers patients aged 12 years and older with body weight greater than 60 kg and obesity, and its safety and effectiveness in pediatric patients with type 2 diabetes have not been established. Zepbound, Foundayo and Wegovy tablets are adults only.
Does Saxenda's 60 kg requirement apply to adults?
The Saxenda label words its indication as covering "adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity," without separating the weight criterion by age. A separate clause covers adults with overweight in the presence of at least one weight-related comorbid condition.
What health conditions pair with overweight to meet the label?
The labels do not publish a list of qualifying comorbid conditions — the phrase "at least one weight-related comorbid condition" appears without a definition. Related sources note obesity's link to type 2 diabetes risk and GLP-1 promise in cardiovascular disease, obstructive sleep apnea and substance use disorder, but which conditions count is ultimately a plan and prescriber decision.
Who is absolutely barred from taking these drugs?
Every label in this group — Wegovy, Zepbound, Foundayo, Saxenda and Ozempic — contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2, and each lists hypersensitivity to the active drug or its excipients as a contraindication. All carry a boxed warning about thyroid C-cell tumor risk, whose human relevance is undetermined.
Does sleep apnea open a separate coverage route?
Zepbound carries a separate indication to treat moderate to severe obstructive sleep apnea in adults with obesity. Whether a plan covers a drug under that indication, and on what terms, is a plan decision — employers apply their own coverage rules and formulary exclusions, and 67% of surveyed employers currently cover GLP-1s for weight management.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.